Welcome to BioSeeker Group!

Triple Analysis: Apoptosis, Angiogenesis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4334
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Apoptosis, Angiogenesis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Angiogenesis and Peptides.

    To find out more about Triple Analysis: Apoptosis, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Arana Therapeutics
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Avila Therapeutics
Basilea Pharmaceutica
Baxter International
Bayer
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinuvel
CombinatoRx
Compugen
Coronado Biosciences
Critical Outcome Technologies
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Digna Biotech
Dongkook Pharm
Dyax
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
EpiCept
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
GP Pharm
GPC Biotech
Green Cross
Gryphon Therapeutics
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
ImmunoGen
Immunotope
ImmuPharma
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kalypsys
Karus Therapeutics
Karyon-CTT
Keryx Biopharmaceuticals
Kirax
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
NewSouth Innovations
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
NPS Pharmaceuticals
Oasmia
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Progen
ProMetic Life Sciences
Protagonist
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
Shionogi
Shire
Sigma-Tau
Simcere Pharmaceuticals
Soligenix
Spear Therapeutics
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
SuperGen
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
SynDevRx
Tactic Pharma
Taiho
Takeda
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
UCB
UMN Pharma
Unigene
United Biomedical
ValiRx
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
ViroTarg
VM Discovery
Xerion
Xigen
Zelos Therapeutics
Zensun
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEG-35156
AEZS-108
afamelanotide
aflibercept
alvocidib
AME-133
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
APG-101
ARQ-197
AS-101
AS-1411
atrasentan
axitinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
BMS-690514
bortezomib
bosutinib
brivanib alaninate
BZL-101
canfosfamide hydrochloride
CBP-501
cediranib
cenersen
cilengitide
cintredekin besudotox
conatumumab
corticorelin acetate
crolibulin
deslorelin
DI-17E6
dinaciclib
dovitinib lactate
dulanermin
E-75
E-7820
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
EP-100
everolimus
Exherin
foretinib
fosbretabulin tromethamine
FPI-01
gataparsen
GliaAtak
goserelin
GT-111
GV-1001
GX-301
HBP-347
HE-3235
Her-2/Neu peptides
histrelin
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
imetelstat
imMucin
intetumumab
IPP-204106
ISA-P53-01
JI-101
kahalalide F
lanreotide
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
litronesib
lonaprisan
lumiliximab
LY-2275796
mapatumumab
MDX-1379
MGCD-265
midostaurin
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
NAFB001
navitoclax
netupitant
NGR-TNF
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ON-01910
Oncohist
OTS-102
ozarelix
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pegdinetanib
PF-4856884
plitidepsin
polyclonal antibody stimulator
ponatinib
ProstAtak
PTC-299
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
ridaforolimus
rindopepimut
romurtide
sagopilone
seliciclib
sirolimus
sorafenib tosylate
sotatercept
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
tivozanib
TL-32711
TM-30339
TRC-105
triciribine phosphate
TRU-016
vandetanib
vapreotide, immediate-release
vismodegib
vitespen
volasertib
volociximab
vosaroxin
VX-001
XL-147
XL-184
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Angiogenesis and Peptides.
    To find out more about Triple Analysis: Apoptosis, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Pancreatic Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the compound strategy of Antibodies. Learn More


Triple Analysis: Lymphoma, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Cancer Vaccines Fantasy or Future?
In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements. Learn More